Literature DB >> 10052886

Monte Carlo calculation of the dose distributions of two 106Ru eye applicators.

A Sánchez-Reyes1, J I Tello, B Guix, F Salvat, J J Tello.   

Abstract

BACKGROUND AND
PURPOSE: Beta emitting 106Ru applicators are widely used to treat choroidal melanoma. In view of the importance of clinical applications of this radioisotope and the relative lack of knowledge of the dose distributions, three-dimensional dose maps of two concave applicators were calculated by means of Monte Carlo simulation.
MATERIALS AND METHODS: Simulations of small CCA and CCB concave applicators manufactured by Bebig were performed using the Monte Carlo code PENELOPE, which allows the description of the structure (geometry and materials) of the applicator in detail. Electrons are emitted from the 106Ru nuclei isotropically, with initial energy randomly sampled from the corresponding Fermi spectra and with initial positions uniformly distributed on the radioactive layer. Primary electrons, as well as the produced delta-rays, are assumed to be absorbed in the medium when they slow down to an energy of 70 keV. Bremsstrahlung photons with energies larger than 7 keV are also simulated. The simulation code has been run on a 166 MHz PENTIUM PC.
RESULTS: Three-dimensional dose distributions produced by the CCA and CCB applicators in a water sphere, concentric with the applicator, were evaluated. To minimize the magnitude of statistical uncertainties, advantage has been taken of the cylindrical symmetry of the problem. The relative depth-dose (along the symmetry axis of the applicator) was also evaluated from the applicator surface up to distances larger than I cm, with statistical uncertainties of a few percent. Results compare well with data supplied by the manufacturer.
CONCLUSIONS: We have performed accurate Monte Carlo calculations of three-dimensional dose distributions from CCA and CCB 106Ru applicators. The results, presented in the form of two-dimensional maps, depth-dose distributions along the symmetry axis and lateral dose profiles, provide a detailed description of the dose delivered in treatments of choroidal melanoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10052886     DOI: 10.1016/s0167-8140(98)00095-4

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Monte Carlo Estimation of Absorbed Dose Distributions Obtained from Heterogeneous 106Ru Eye Plaques.

Authors:  Francisco J Zaragoza; Marion Eichmann; Dirk Flühs; Wolfgang Sauerwein; Lorenzo Brualla
Journal:  Ocul Oncol Pathol       Date:  2017-02-23

2.  Accurate estimation of dose distributions inside an eye irradiated with 106Ru plaques.

Authors:  L Brualla; J Sempau; F J Zaragoza; A Wittig; W Sauerwein
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

3.  Monte Carlo Simulation of the Treatment of Eye Tumors with (106)Ru Plaques: A Study on Maximum Tumor Height and Eccentric Placement.

Authors:  Lorenzo Brualla; Francisco J Zaragoza; Wolfgang Sauerwein
Journal:  Ocul Oncol Pathol       Date:  2014-05-07

4.  Monte Carlo Computation of Dose-Volume Histograms in Structures at Risk of an Eye Irradiated with Heterogeneous Ruthenium-106 Plaques.

Authors:  Francisco J Zaragoza; Marion Eichmann; Dirk Flühs; Beate Timmermann; Lorenzo Brualla
Journal:  Ocul Oncol Pathol       Date:  2020-07-20

5.  Monte Carlo Simulation of the Treatment of Uveal Melanoma Using Measured Heterogeneous 106Ru Plaques.

Authors:  Francisco J Zaragoza; Marion Eichmann; Dirk Flühs; Andrea Wittig; Wolfgang Sauerwein; Lorenzo Brualla
Journal:  Ocul Oncol Pathol       Date:  2018-10-15

6.  Gold nanoparticle-based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye.

Authors:  Somayeh Asadi; Mehdi Vaez-zadeh; S Farhad Masoudi; Faezeh Rahmani; Courtney Knaup; Ali S Meigooni
Journal:  J Appl Clin Med Phys       Date:  2015-09-08       Impact factor: 2.102

7.  Monte Carlo simulation of tilted contact plaque brachytherapy placement for juxtapapillary retinoblastoma.

Authors:  Satoshi Nakamura; Naoya Murakami; Shigenobu Suzuki; Kimiteru Ito; Mihiro Takemori; Hiroki Nakayama; Keita Kaga; Takahito Chiba; Kotaro Iijima; Kana Takahashi; Tomonori Goka; Jun Itami; Hiroyuki Okamoto; Hiroshi Igaki
Journal:  Radiat Oncol       Date:  2022-01-24       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.